These findings contribute to our understanding of the molecular mechanisms involved in prostate cancer progression and provide a basis for further investigation into the therapeutic potential of targeting DAX1 and the Hh pathway in prostate cancer treatment. This evidence concerns the gene NR0B1 and Familial prostate cancer.